Sumit Singhal Sumit Singhal loves modern architecture. He comes from a family of builders who have built more than 20 projects in the last ten years near Delhi in India. He has recently started writing about the architectural projects that catch his imagination.
CinnaGen Pharmaceutical company-SD5 in Karaj, Iran by Modaam Architects
January 10th, 2020 by Sumit Singhal
Article source: Modaam Architects
With a total built area of 20000 square meters, this dual complex was designed to serve the needs of Cinnagen biopharmaceutical company headquarters. The complex consists of two separate yet attached volumes: a warm, cozy, brownish brick building as the administrative zone with its inner small gardens for each office, and a second building dedicated to the production zone with its white patterned surface. These two volumes are connected to each other with different pedestrian bridges in different parts of the two buildings.
The challenge of this project was to design a factory consisting different interwoven spaces and functions. These functions included production spaces, storage, technical facilities, administrative spaces, offices, and labs. They had to be integrated in a complex of different open, closed, and semi-closed volumes. The solution was to link three different masses with three different functional roles: a mass for the technical facilities, a mass for production spaces, supportive functions, and storages, and finally a mass include labs, offices and administrative functions.
These masses were later developed. The facilities and production masses were designed as a huge white cube with a semi-transparent skin. The mass of administrative and office functions was located on a glass cube, shaping the lobby with its high ceiling. A delicate brick volume was later put on the glass cube, creating green open spaces for the employees and workers to breath and enjoy the greenery of the elevated trees of the complex.
This entry was posted
on Friday, January 10th, 2020 at 7:01 am.
You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, or trackback from your own site.